

European Commission Publishes Updated Q&A on Clinical Trials Regulation

January 13, 2023

In December 2022, the European Commission [published an updated version of the Q&A guidance](#) on the Clinical Trials Regulation (CTR). This new version was issued ahead of the 31 January 2023 deadline from which all new applications for the approval of clinical trials must be submitted in accordance with the CTR.

The most important amendment to the Q&A is the inclusion of a new Annex III.

The application dossier for the approval of a clinical trial in accordance with the CTR is composed of two parts. Part I of the application dossier relates to scientific aspects of clinical trials that are considered to be scientifically harmonized among European Economic Area (EEA) countries. Part II relates to country-specific, patient-level requirements, which may vary from one EEA country to another. The European Commission has developed standardized templates for documentation required for Part II of the application dossier, but some EEA countries have developed their own national templates.

As a result, when operating in the EEA, sponsors may be confronted with divergent national requirements of individual EEA countries. The updated Q&A aims to provide a consolidated list of national sources where sponsors can identify national requirements and any applicable templates in those countries. This information should assist sponsors in navigating the specific requirements of individual EEA countries, as well as submitting high-quality and appropriate documents as part of their application dossiers for the approval of clinical trials.

Annex III provides a table listing the websites of all EEA countries, where sponsors can find information regarding national requirements of each EEA country. It also lists the email addresses for those countries' national competent authorities to which sponsors may submit inquiries.

Cooley legal trainee [Anastasia Vernikou](#) also contributed to this alert.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered **Attorney Advertising** and is subject to our [legal notices](#).

Jessica Koffel Brussels	jkoffel@cooley.com +32 2 486 75 25
----------------------------	---------------------------------------

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.